HC Wainwright & Co. reiterates Buy rating on SpyGlass Pharma, $37 price target

HC Wainwright & Co. maintained a Buy rating on SpyGlass Pharma with a $37 price target, implying 48.5% upside. The company's BIM-IOL System is in Phase 3 trials, and its acquisition of Advanced Vision Science enhances manufacturing capabilities. The stock closed at $24.92 on Oct 2.

Original reporting
Published Oct 5, 2026, 12:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 12:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. reiterates Buy rating on SpyGlass Pharma, $37 price target — source image
Decision brief

The 30-second read

Med
01

Why it matters

Analyst upgrade could attract buying pressure, but trial outcomes remain uncertain.

02

Market read

Analyst rating change provides a fresh catalyst for the micro‑cap biotech.

03

What to watch

Funding needs for Phase 3 trial and regulatory risk

Relevance 7/10Novelty 6/10Timing: today

Background

Analyst reiterates Buy rating with $37 price target for SpyGlass Pharma.

Market effects

Potential uplift for glaucoma treatment sector

Limited to US biotech investors

Modest, confined to niche ophthalmology market

Counterpoint

Rating may be premature without trial data release

Key entities

  • SpyGlass Pharma

    Biotech firm developing intraocular drug delivery system.

Related articles

$SGPMed

SpyGlass Pharma at Citigroup summit: glaucoma lens nears phase iii

SpyGlass Pharma (SGP) presented at Citigroup’s Biopharma Summit, outlining plans for its BIM-IOL drug-device platform. The company reported strong clinical data, with 95% of patients free of additional glaucoma therapy at three years in early trials. SpyGlass has $234 million in cash, expects Phase III trial completion in 2028, and aims for a 2029 launch. The company targets a market of 200,000 annual cataract procedures in the U.S. with glaucoma.

$SGPMed

SpyGlass Pharma Expands to Bigger HQ in Irvine

SpyGlass Pharma Inc. (Nasdaq: SGP) has moved to a larger headquarters in Irvine, accommodating up to 150 employees. The biopharmaceutical company, which went public in February, is focused on drug delivery solutions for chronic eye conditions. It is currently conducting Phase 3 trials for its lead product, the BIM-IOL system, with a target launch in 2029. The company's stock traded at $28.99 with a $970 million market cap, up 77% since its IPO. SpyGlass has also secured a new AMA Category III co

$SGPMed

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. •

$EQNRMed

Galp Energia and Equinor Get Offshore Brazilian Oil Block

Galp Energia and Equinor have been awarded an offshore oil block in Brazil's Santos Basin. Galp will own 30% of the Rodocrosita block, with Equinor operating the remaining 70%. The companies may explore synergies with the adjacent Bacalhau project, which is ramping up production and will contribute 40,000 barrels per day to Galp once fully operational.

$PINSMed

Pinterest (PINS), Why Is It Back In The Spotlight?

Pinterest (PINS) appointed Amazon's James Dibbo as its new CFO. The company's stock has shown mixed performance, with a recent 7-day return of 7.52% but a 1-year return of -36.11%. Analysts have varying views on its valuation, with some seeing it as undervalued at $20.31 per share compared to a fair value estimate of $29.05, while others note its high P/E ratio of 46.2x.